ORG	Race-Based
ORG	Medicine
QUE	?
NIL	PALO ALTO
NIL	–
CON	Race
POS	can
EXT	undoubtedly
EXS	be
DIS	a
EXS	tricky
IST	subject
NIL	,
REL	with
AND	any
CON	suggestion
AND	of
IST	genetic
CON	differences
AND	among
IST	racial
CON	groups
NIL	–
AND	beyond
IST	superficial
CON	characteristics
AND	like
CON	skin
CON	color
NOW	–
INT	potentially
EXS	invoking
CON	memories
AND	of
DEF	the
IST	nineteenth-century
CON	eugenics
CON	movement
AND	and
HAS	its
IST	eventual
CON	role
REL	in
IST	Nazi
CON	ideology
NIL	.
AND	Now
NIL	,
REL	with
CON	drug
CON	companies
IST	increasingly
EXS	seeking
SUB	to
EXS	develop
CON	medications
SUB	that
ENS	target
IST	particular
IST	racial
CON	groups
NIL	,
DEF	the
CON	long-taboo
CON	subject
AND	of
IST	racial
CON	genetics
NOW	has
EXS	reemerged
NIL	.
QUC	Much
AND	of
DEF	the
IST	current
CON	debate
CON	centers
REL	on
QUE	whether
CON	race
NEC	should
EXS	be
DIS	a
CON	criterion
REL	for
CON	inclusion
REL	in
IST	clinical
CON	trials
NIL	–
AND	and
NIL	,
REL	by
CON	extension
NIL	,
SUB	whether
CON	drug
CON	labeling
NEC	should
EXS	mention
CON	race
IST	specifically
NIL	.
SUB	Although
DEF	the
CON	issues
NOW	are
EXS	complicated
NIL	,
DEF	the
CON	solution
NOW	is
EXS	simple
COO	:
EXS	follow
DEF	the
CON	data
NIL	.
REL	In
CON	fact
EQU	,
IST	clinical
CON	trials
NOW	are
NOT	not
EXS	intended
SUB	to
EXS	demonstrate
DEF	the
CON	effectiveness
AND	of
DIS	a
CON	treatment
SUB	(
CON	drug
EQU	,
IST	medical
CON	device
NIL	,
DIS	or
ALT	other
CON	intervention
NIL	)
REL	in
DIS	a
IST	completely
IST	random
CON	sample
REL	from
DEF	the
IST	general
CON	population
NIL	.
AND	Rather
NIL	,
CON	researchers
NIL	“
EXS	enrich
AND	”
DEF	the
CON	study
CON	population
REL	by
EXS	using
DIS	a
CON	characteristic
NIL	,
AND	such
AND	as
CON	age
DIS	or
IST	laboratory-test
CON	results
NIL	,
SUB	to
EXS	select
DIS	a
CON	subset
AND	of
CON	patients
REL	in
UNK	whom
DEF	the
CON	intervention
AND	’s
CON	effects
FUT	will
IST	likely
EXS	be
UNK	easier
SUB	to
EXS	detect
AND	than
PRO	they
FUT	would
EXS	be
REL	in
DIS	an
IST	unfiltered
CON	population
NIL	.
REL	In
IST	recent
CON	years
EQU	,
IST	“
CON	biomarkers
NIL	,
NIL	”
AND	such
AND	as
IST	certain
CON	DNA
CON	sequences
DIS	or
DEF	the
CON	presence
AND	of
DIS	a
IST	particular
CON	drug
CON	receptor
NIL	,
NOW	have
EXS	become
INT	increasingly
IST	important
CON	indicators
REL	for
EXS	determining
CON	eligibility
REL	for
IST	clinical
CON	trials
NIL	.
PRX	This
CON	approach
NOW	is
NOT	not
IST	new
NIL	.
REL	For
CON	example
COO	,
ROL	scientists
NOW	have
EXS	known
REL	for
CON	decades
AND	that
IST	certain
CON	drugs
POS	can
EXS	cause
IST	severe
AND	and
IST	precipitous
GEO	anemia
REL	in
CON	people
REL	with
DIS	a
IST	genetic
CON	deficiency
AND	of
DEF	the
CON	enzyme
CON	G6PD
NIL	.
MOR	More
IST	recently
NIL	,
CON	researchers
NOW	have
EXS	learned
SUB	that
IST	certain
CON	cancer
CON	drugs
NOW	are
EXS	ineffective
REL	in
EXG	fighting
CON	tumors
EXS	containing
DEF	the
IST	mutated
CON	variant
AND	of
DEF	the
IST	gene
CON	KRAS
NIL	.
AND	Such
CON	discoveries
NOW	have
EXT	enhanced
CON	researchers
AND	’
CON	ability
SUB	to
EXS	enrich
CON	study
CON	populations
REL	with
CON	patients
AND	who
NOW	are
UNK	likely
SUB	to
EXS	benefit
REL	from
DEF	the
CON	drug
NIL	,
SUB	while
EXS	sparing
REL	from
DIS	any
IST	possible
CON	side
CON	effects
AND	of
CON	exposure
DST	those
CON	patients
AND	who
NOW	are
UNK	unlikely
SUB	to
EXS	benefit
NIL	.
CON	Enrichment
IST	thus
NOW	enables
CON	researchers
SUB	to
EXS	strengthen
IST	clinical
CON	trials
AND	’
DEF	“
IST	statistical
CON	power
NIL	,
NIL	”
DST	that
NOW	is
NIL	,
DEF	the
CON	probability
AND	of
EXS	detecting
CON	differences
NIL	,
IMP	if
AND	any
ENS	exist
NIL	,
REL	between
CON	study
CON	groups
NIL	.
AND	Given
AND	that
DIS	a
MOR	larger
CON	number
AND	of
CON	subjects
DIS	or
CON	iterations
CON	enhances
DIS	an
CON	experiment
AND	’s
CON	ability
SUB	to
EXS	detect
AND	all
AND	of
DEF	the
IST	relevant
CON	effects
NIL	,
AND	which
CON	bolsters
CON	confidence
REL	in
DEF	the
CON	result
EQU	,
CON	outcomes
AND	of
IST	small
CON	studies
ENS	tend
SUB	to
EXS	imply
IST	significant
CON	uncertainty
NIL	–
SUB	unless
DEF	the
CON	intervention
AND	’s
CON	effects
NOW	are
IST	potent
NIL	.
ORG	Enrichment
NOW	allows
CON	researchers
SUB	to
EXS	perform
MOR	smaller
NIL	,
MOR	more
IST	informative
CON	trials
REL	by
EXS	helping
PRO	them
SUB	to
EXS	design
CON	studies
AND	that
FUT	will
EXS	show
DIS	a
IST	high
IST	“relative
CON	treatment
CON	difference
NIL	”
REL	between
DEF	the
CON	drug
AND	and
QUE	whatever
PRO	it
NOW	is
EXS	being
AND	compared
SUB	to
SUB	(
IST	often
DIS	a
CON	placebo
NIL	,
BUT	but
DIS	sometimes
ALT	another
CON	treatment
NIL	)
NIL	.
REL	In
DEF	the
CON	1980
CON	s
EQU	,
DIS	a
CON	biomarker
EPS	contributed
REL	to
DEF	the
CON	success
AND	of
DEF	the
IST	small
COO	but
IST	seminal
IST	clinical
CON	trial
AND	of
IST	human
CON	growth
CON	hormone
REL	in
CON	children
AND	who
PST	were
UNK	unable
SUB	to
EXS	produce
PRO	it
IST	naturally
NIL	.
DIS	Some
CON	children
EXS	lose
DEF	the
CON	ability
SUB	to
EXS	make
CON	growth
CON	hormone
IST	due
REL	to
CON	injury
DIS	or
CON	tumors
COO	;
ALT	others
NOW	lack
IST	normal
CON	growth-hormone
CON	activity
REL	from
CON	birth
NIL	,
EXS	owing
REL	to
DIS	a
IST	genetic
CON	mutation
NIL	;
COO	and
ALT	others
NOW	are
EXS	missing
DEF	the
CON	gene
AND	that
CON	codes
REL	for
DEF	the
CON	hormone
IST	altogether
NIL	.
